---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-063157"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-06-01T12:01:20+00:00"
generated_at: "2026-06-01T12:06:10.718204+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics initiates strategic review including potential sale or wind-down

## Summary
- Board of Directors initiates comprehensive review of strategic alternatives to maximize shareholder value.
- Options include sale of assets/licensing, collaboration, merger, business combination, or orderly wind-down.
- Company to continue evaluating cost-saving measures to preserve cash during the process.
- No defined timeline for the review; no assurance any transaction will be consummated.

## SEC filing metadata
- accession: 0001213900-26-063157
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-06-01T12:01:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/0001213900-26-063157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/ea0292909-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-063157
- JSON: https://secwatch.observer/filing/0001213900-26-063157.json
- Plain text: https://secwatch.observer/filing/0001213900-26-063157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.